Mycobacterium tuberculosis (Mtb) is one of the world's most successful pathogens. WHO estimates that about one third of the world's population has a positive skin test that reflects a long-term adaptive immune response to Mtb antigens. These individuals are considered to have actual or potential latent Mtb infection (LTBl). Among them, a minority that cannot be identified prospectively will develop reactivation tuberculosis (TB) despite having apparently normal immunity. Active TB can be contagious both to those who were previously unexposed and those with LTBl and is usually lethal if untreated. Adequate numbers of CD4 T cells, tumor necrosis factor alpha (TNF?), and interferon-gamma (IFN?) are validated determinants of control of primary TB, but the vast majority of HIV negative patients with reactivation TB do not have defined defects in these pathways. The ability of Mtb to remain latent within the human host, and the related failure of the human immune system to sterilize Mtb in latently infected individuals, are poorly understood. Antimicrobial therapy for active infection by drug-sensitive Mtb is effective, but current drugs must be given for 6 months to achieve relapse-free cure rates of >95%. The necessity for this prolonged duration of therapy is attributable to the ability of genetically drug-sensitive Mtb to adopt a phenotypically drug-tolerant, persistent state in which it is not readily sterilized by current drugs. Despite substantal efforts to understand these two critical features of Mtb infection-latency and persistence-fundamental questions remain about the genetic, immunologic, and microbiologic contributors to both. We seek to close this knowledge gap through a Tuberculosis Research Unit (TBRU) that unites investigators at Weill Cornell Medical College (WCMC), Rockefeller University (RU), and Memorial Sloan Kettering Cancer Center (MSKCC), with selected external collaborators, and draws on patients at the WMC-affiliated GHESKIO Centers in Haiti to provide insight into latency and persistence of Mtb during human infection.

Public Health Relevance

This multi-institutional TBRU will deliver new insights into the ability of M. tuberculosis to resist elimination by the human immune system during latency and by antimicrobials during drug treatment for tuberculosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI111143-01
Application #
8691646
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Sizemore, Christine F
Project Start
2014-07-01
Project End
2021-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10065
Namasivayam, Sivaranjani; Maiga, Mamoudou; Yuan, Wuxing et al. (2017) Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome 5:71
Botella, Laure; Vaubourgeix, Julien; Livny, Jonathan et al. (2017) Depleting Mycobacterium tuberculosis of the transcription termination factor Rho causes pervasive transcription and rapid death. Nat Commun 8:14731
Salerno Jr, Stephen; Mehrmohamadi, Mahya; Liberti, Maria V et al. (2017) RRmix: A method for simultaneous batch effect correction and analysis of metabolomics data in the absence of internal standards. PLoS One 12:e0179530
Hartman, Travis E; Wang, Zhe; Jansen, Robert S et al. (2017) Metabolic Perspectives on Persistence. Microbiol Spectr 5:
Saito, Kohta; Warrier, Thulasi; Somersan-Karakaya, Selin et al. (2017) Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations. Proc Natl Acad Sci U S A 114:E4832-E4840
Eoh, Hyungjin; Wang, Zhe; Layre, Emilie et al. (2017) Metabolic anticipation in Mycobacterium tuberculosis. Nat Microbiol 2:17084
Wipperman, Matthew F; Fitzgerald, Daniel W; Juste, Marc Antoine Jean et al. (2017) Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci Rep 7:10767
Jansen, Robert S; Rhee, Kyu Y (2017) Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome. Trends Pharmacol Sci 38:393-405
Nathan, Carl (2017) Kunkel Lecture: Fundamental immunodeficiency and its correction. J Exp Med 214:2175-2191
Hsu, Hao-Chi; Singh, Pradeep K; Fan, Hao et al. (2017) Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome. Biochemistry 56:324-333

Showing the most recent 10 out of 25 publications